Eudaimonia Partners’s Repligen RGEN Stock Holding History

Eudaimonia Partners’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-30	Closed	-$6K	–	1142
2021 Q1	$6K	Buy	+30	New	+$6.15K	﹤0.01%	1296

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Eudaimonia Partners's RGEN Position: Q2 2021 in Review

Eudaimonia Partners sold out of Repligen (RGEN) in Q2 2021, closing a stake of 30 shares — an estimated $6K sold.

Eudaimonia Partners first reported a position in RGEN in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 428 funds tracked by Wall St. Rank hold RGEN as of Q2 2021.

Eudaimonia Partners reported no remaining Repligen position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 30 Repligen shares in Q2 2021, an estimated $6K.
Eudaimonia Partners first reported a position in Repligen in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Repligen position peaked at $6K in Q1 2021.
428 funds tracked by Wall St. Rank held Repligen as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.